Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Modello Hospital @ Home di cura per la cirrosi (H@H)

17 settembre 2026 aggiornato da: Archita P. Desai, Indiana University

Il modello di cura Hospital @ Home: una nuova soluzione sanitaria per la gestione della cirrosi scompensata

The purpose of this study is to work with patients diagnosed with end-stage liver disease to understand their perspectives on the Health at Home (H@H) Program, including desired outcomes and expectations, perceived barriers, and drivers. H@H is an emerging model of home-based care, designed to extend traditional, inpatient hospital care which may address these needs. Through H@H, acute medical care services as well as ancillary care such as rehabilitation therapy can be delivered in the home. The study is divided into three phases: Phase 1 occurs while the participant is an inpatient. Phase 2 is when the actual H@H program takes place as part of the participant's clinical care. The study team will not be involved in the Phase 2 - H@H program as it will be conducted by the clinical staff. Phase 3, at which point the participant enters a rehabilitation phase to transition the patient to self-management, involves a research jam session with the participant and caregiver to assess the value of the program.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Descrizione dettagliata

Hospital at Home (H@H) as an emerging model of care is designed as an extension for traditional inpatient hospital care. Patients experiencing certain medical conditions normally requiring admission to an inpatient hospital can instead consent to receive acute care treatment in their homes. Prior studies have shown success of this model through demonstration of clinical and economic efficacy and feasibility, as well as greater satisfaction with care for patients, their family members and their providers. Since November 2020, Centers for Medicare and Medicaid Services has provided a waiver for H@H services. Similarly in 2020, Indiana University Health (IUH) introduced the Hospital at Home (H@H) Program for its beneficiaries to increase hospital capacity during the Public Health Emergency. Through this program, primary medical management services as well as ancillary services such as Occupational Therapy, Physical Therapy, and diagnostic testing can be delivered in the home. This model has been successful used at IUH to management patients with moderate COVID-19 infection, common infectious diseases, and decompensated heart failure.

In the realm of liver disease, acute decompensations of chronic liver disease often require hospitalizations for acute management. In certain clinical scenarios, while the initial 24-48 hour period may require the intensive management offered in an acute care hospital, the remaining hospital days represent less acute and/or intense needs such as continued administration of IV medications, monitoring for safe transition to oral medications and/or daily lab monitoring for period of time. We hypothesize that services through the IUH H@H program can offer equally safe and effective for these clinical scenarios while improving patient satisfaction, reducing care-giver burden, being cost-saving and improving access to acute care hospital services to other patients. We also hypothesize that completing the acute care management in the home setting will lead to more effective transition to chronic management as measured by subsequent 30-day readmissions and 30-day emergency room visits leading to reduced overall cost of health care. As a next step in expansion, the IUH H@H team is partnering with the PI and IUH Hepatology team to manage select patients with chronic liver disease (CLD). The overall goal of this proposal is to assess whether IUH's H@H program represents a novel care delivery model in cirrhosis that is safe, improves patient and caregiver experience as well as reduces HCU in the high-risk, CLD population.

Tipo di studio

Interventistico

Iscrizione (Stimato)

30

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Regia Weber
  • Numero di telefono: 317-278-3584
  • Email: reginaw@iu.edu

Backup dei contatti dello studio

  • Nome: Archita Desai, MD
  • Numero di telefono: (317) 278-1664
  • Email: desaiar@iu.edu

Luoghi di studio

    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46202
        • Reclutamento
        • IU School of Medicine
        • Contatto:
          • Miranda Stovall
          • Numero di telefono: (317) 278-2401
          • Email: mirstova@iu.edu

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Enrolled into IUH's H@H program
  • At least 18 years of age
  • Chronic liver disease/cirrhosis based on characteristic clinical, laboratory, and imaging findings
  • English speaking
  • Able to provide consent
  • Caregiver able to be present during the acute phase of care (first 48 hours post-hospital discharge)
  • Able to perform activities of daily living independently
  • Lives within IU Health Home service area

Exclusion Criteria:

  • Unable to complete study questionnaires due to neurocognitive disease, legal blindness or hearing loss
  • Transplant of organ other than liver
  • Pregnant
  • Incarcerated
  • New hemodialysis
  • Blood pressure < 90/60, Pulse > 120, O2 > 6L or >2L above baseline
  • HIV+/CD4 count < 200
  • Receiving hospice services
  • Concurrent enrollment in a related research study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Altro: Decompensated Cirrhotics

Phase 1:

  • two questionnaires to assess patient reported outcomes
  • an open-ended patient interview using a variety of patient-engagement methods to assess program expectations

Phase 2:

• completion of the Hospital at Home (H@H) program as part of clinical care. In brief, the Hospital at Home program (H@H) is an innovative care delivery method that aims to provide hospital-level care at home and facilitate the transition care from the hospital to the home.

Phase 3:

  • researchers engage virtually to discuss actual experience, outcomes, and challenges. These will be semi-structured interviews about their perspectives on the program, including desired outcomes and expectations and perceived barriers and drivers and will last about two hours.
  • complete four questionnaires relating to quality of life.

Structure of Care in IUH H@H Program: The IUH H@H program allows patients to be cared for at home using home remote monitoring devices, travel laboratory services and both in-person and virtual rounding by the health care team. The team includes registered nurses (RN), advanced practice provider (APP, nurse practitioner and physician assistants) and hospitalist physician. Care at home is divided into 4 consecutive phases after initial hospitalization: (1) evaluation/planning, (2) acute, (3) recovery, and (4) rehabilitation. All patients are sent home with a RPM tablet used to obtain vital signs, send messages between patient and RN, & perform video visits. The device is Bluetooth enabled and does not require WiFi or a phone line. All data obtained is automatically pulled into the electronic medical record. The RN uses a device which enables remote physical exams, i.e., obtain heart, lung and bowel sounds, pictures (wounds, lines, etc.) for review by APP/MD.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Number of participants enrolled into program
Lasso di tempo: Phase 1 Baseline
Phase 1 Baseline
Reason for enrollment failure
Lasso di tempo: Phase 1 Baseline
Phase 1 Baseline

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of participants with follow-up consultations during Phase 2
Lasso di tempo: During H@H program and up to and including 90 days after program completion
During H@H program and up to and including 90 days after program completion
Number of participants with services utilized in the home during Phase 2
Lasso di tempo: During H@H program and up to and including 90 days after program completion
During H@H program and up to and including 90 days after program completion
Number of participants with ED visits
Lasso di tempo: During H@H program and up to and including 90 days after program completion

ED visits, including repeat visits, will be tracked

During H@H program and up to and including 90 days after program completion
Number of participants with rehospitalization
Lasso di tempo: During H@H program and up to and including 90 days after program completion
During H@H program and up to and including 90 days after program completion
Number of participants with a liver transplant
Lasso di tempo: 30 and 90 days after H@H program completion
30 and 90 days after H@H program completion
Number of participants with hospice enrollment
Lasso di tempo: 30 and 90 days after H@H program completion
30 and 90 days after H@H program completion
Rate of Mortality
Lasso di tempo: up to 90 days after H@H program completion
up to 90 days after H@H program completion
PSQ 18
Lasso di tempo: at 2 weeks after H@H program completion

Patient Satisfaction Questionnaire

at 2 weeks after H@H program completion
Telemedicine Questionnaire
Lasso di tempo: at 2 weeks after H@H program completion
at 2 weeks after H@H program completion
ZBI-12
Lasso di tempo: at 2 weeks after H@H program completion

Zarit Burden Interview Questionnaire

at 2 weeks after H@H program completion
Promis 29+2
Lasso di tempo: up to 90 days after H@H program completion

change in health related quality of life

up to 90 days after H@H program completion

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 maggio 2024

Completamento primario (Stimato)

30 settembre 2028

Completamento dello studio (Stimato)

31 dicembre 2028

Date di iscrizione allo studio

Primo inviato

30 aprile 2024

Primo inviato che soddisfa i criteri di controllo qualità

30 aprile 2024

Primo Inserito (Effettivo)

2 maggio 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 21905

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi